Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biosyent Inc BIOYF


Primary Symbol: V.RX

Healthcare
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing... see more

Recent & Breaking News (TSXV:RX)

BioSyent Pharma Submits Two New Drugs to Health Canada for Marketing Approval

Marketwired May 23, 2013

BioSyent Releases First Quarter Results-Sales Increase 70%, Profit Before Tax Up 76%

Marketwired May 22, 2013

Confirmation of BioSyent Inc. 2013 AGM Location

Marketwired May 17, 2013

BioSyent Releases Full Year 2012 Results-Sales Increase 79%, Net Income Up 267%; 3 Year CAGR 70%; Q4 Sales Increase 89%

Marketwired March 21, 2013

BioSyent Releases Full Year 2012 Results-Sales Increase 79%, Net Income Up 267%; 3 Year CAGR 70%; Q4 Sales Increase 89%

MarketWire Canada March 21, 2013

BioSyent Named to the 2013 TSX Venture Top 50(R) Ranking-2nd Consecutive Year Chosen as a Top TSX Performer

MarketWire Canada February 14, 2013

BioSyent Presents at MicroCapClub Invitational

MarketWire Canada February 12, 2013

Canadian small/micro-cap weekend roundup

Stockhouse Editorial November 19, 2011

Junior miner jumps on gold resource estimate

Sean Mason November 16, 2011

Stockhouse @ the Bell: U.S. stocks up on energy rebound

Stockhouse Editorial June 2, 2010